218 related articles for article (PubMed ID: 22404500)
1. Everolimus: preventing organ rejection in adult kidney transplant recipients.
Dantal J
Expert Opin Pharmacother; 2012 Apr; 13(5):767-78. PubMed ID: 22404500
[TBL] [Abstract][Full Text] [Related]
2. A drug safety evaluation of everolimus in kidney transplantation.
Holdaas H; Midtvedt K; Åsberg A
Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349
[TBL] [Abstract][Full Text] [Related]
3. Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen.
Carvalho C; Coentrão L; Bustorff M; Patrício E; Sampaio S; Santos J; Oliveira G; Pestana M
Clin Transplant; 2011; 25(4):E401-5. PubMed ID: 21457330
[TBL] [Abstract][Full Text] [Related]
4. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
5. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J
Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739
[TBL] [Abstract][Full Text] [Related]
6. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
7. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
Su L; Tam N; Deng R; Chen P; Li H; Wu L
Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
[TBL] [Abstract][Full Text] [Related]
8. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM
Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177
[TBL] [Abstract][Full Text] [Related]
9. Everolimus in clinical practice in long-term liver transplantation: an observational study.
Casanovas T; Argudo A; Peña-Cala MC
Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
[TBL] [Abstract][Full Text] [Related]
10. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
Helal I; Chan L
Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
[TBL] [Abstract][Full Text] [Related]
11. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
[TBL] [Abstract][Full Text] [Related]
12. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
13. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
Hernández D; Martínez D; Gutiérrez E; López V; Gutiérrez C; García P; Cobelo C; Cabello M; Burgos D; Sola E; González-Molina M
Nefrologia; 2011; 31(1):27-34. PubMed ID: 21270910
[TBL] [Abstract][Full Text] [Related]
14. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
[TBL] [Abstract][Full Text] [Related]
15. Calcineurin inhibitors in renal transplantation still needed but in reduced doses: a review.
Ponticelli C; Scolari MP
Transplant Proc; 2010; 42(6):2205-8. PubMed ID: 20692445
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.
Dantal J; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Quéré S; Di Giambattista F; Cassuto E;
Transpl Int; 2010 Nov; 23(11):1084-93. PubMed ID: 20500493
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine versus everolimus: effects on the glomerulus.
Baas MC; Kers J; Florquin S; de Fijter JW; van der Heide JJ; van den Bergh Weerman MA; ten Berge IJ; Bemelman FJ
Clin Transplant; 2013; 27(4):535-40. PubMed ID: 23795805
[TBL] [Abstract][Full Text] [Related]
18. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
[TBL] [Abstract][Full Text] [Related]
19. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
Nashan B; Gaston R; Emery V; Säemann MD; Mueller NJ; Couzi L; Dantal J; Shihab F; Mulgaonkar S; Seun Kim Y; Brennan DC
Transplantation; 2012 Jun; 93(11):1075-85. PubMed ID: 22683823
[TBL] [Abstract][Full Text] [Related]
20. Association of a change in immunosuppressive regimen with hemodynamic and inflammatory markers of cardiovascular disease after kidney transplantation.
Yong K; Nguyen HD; Hii L; Chan DT; Boudville N; Messineo A; Lim EM; Dogra GK; Lim WH
Am J Hypertens; 2013 Jul; 26(7):843-9. PubMed ID: 23443728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]